实用药物与临床
實用藥物與臨床
실용약물여림상
Practical Pharmacy and Clinical Remedies
2015年
10期
1185-1188
,共4页
左卡尼汀%表柔比星%心脏毒性%紫杉醇%神经毒性
左卡尼汀%錶柔比星%心髒毒性%紫杉醇%神經毒性
좌잡니정%표유비성%심장독성%자삼순%신경독성
Levocarnitine%Epirubicin%Cardiotoxicity%Paclitaxel%Neurotoxicity
目的 观察左卡尼汀预防表柔比星引起的心脏毒性及紫杉醇引起的周围神经毒性的疗效. 方法 40例接受AC→T(表柔比星+环磷酰胺→紫杉醇)方案化疗的乳腺癌患者分成2组,对照组单纯化疗,治疗组在化疗的同时加用左卡尼汀治疗. 比较4个周期表柔比星化疗后心脏毒性发生情况及4个周期紫杉醇化疗后周围神经毒性发生率的差异. 结果 化疗后,对照组与治疗组心电图异常发生率分别为70%、25%,差异有统计学意义(P<0. 05);两组cTnI值分别为(0. 20±0. 12)、(0. 12±0. 08) μg/L,差异有统计学意义(P<0. 05). 两组CK-MB值分别为(25. 15±7. 80)、(20. 05±5. 17) U/L,差异有统计学意义(P<0. 05). 对照组与治疗组周围神经毒性发生率分别为75%、35%,差异有统计学意义(P<0. 05). 结论 化疗同时给予左卡尼汀可减轻表柔比星引起的心脏毒性及紫杉醇引起的周围神经毒性.
目的 觀察左卡尼汀預防錶柔比星引起的心髒毒性及紫杉醇引起的週圍神經毒性的療效. 方法 40例接受AC→T(錶柔比星+環燐酰胺→紫杉醇)方案化療的乳腺癌患者分成2組,對照組單純化療,治療組在化療的同時加用左卡尼汀治療. 比較4箇週期錶柔比星化療後心髒毒性髮生情況及4箇週期紫杉醇化療後週圍神經毒性髮生率的差異. 結果 化療後,對照組與治療組心電圖異常髮生率分彆為70%、25%,差異有統計學意義(P<0. 05);兩組cTnI值分彆為(0. 20±0. 12)、(0. 12±0. 08) μg/L,差異有統計學意義(P<0. 05). 兩組CK-MB值分彆為(25. 15±7. 80)、(20. 05±5. 17) U/L,差異有統計學意義(P<0. 05). 對照組與治療組週圍神經毒性髮生率分彆為75%、35%,差異有統計學意義(P<0. 05). 結論 化療同時給予左卡尼汀可減輕錶柔比星引起的心髒毒性及紫杉醇引起的週圍神經毒性.
목적 관찰좌잡니정예방표유비성인기적심장독성급자삼순인기적주위신경독성적료효. 방법 40례접수AC→T(표유비성+배린선알→자삼순)방안화료적유선암환자분성2조,대조조단순화료,치료조재화료적동시가용좌잡니정치료. 비교4개주기표유비성화료후심장독성발생정황급4개주기자삼순화료후주위신경독성발생솔적차이. 결과 화료후,대조조여치료조심전도이상발생솔분별위70%、25%,차이유통계학의의(P<0. 05);량조cTnI치분별위(0. 20±0. 12)、(0. 12±0. 08) μg/L,차이유통계학의의(P<0. 05). 량조CK-MB치분별위(25. 15±7. 80)、(20. 05±5. 17) U/L,차이유통계학의의(P<0. 05). 대조조여치료조주위신경독성발생솔분별위75%、35%,차이유통계학의의(P<0. 05). 결론 화료동시급여좌잡니정가감경표유비성인기적심장독성급자삼순인기적주위신경독성.
Objective To observe the preventive effect of levocarnitine on cardiomyocyte injury induced by epirubicin and peripheral nerve toxicity caused by paclitaxel. Methods Forty mammary cancer patients treated with AC-T (Epirubicin plus cyclophosphamide-paclitaxel) chemotherapy were randomized into two groups,control group was given chemotherapy,treatment group was given chemotherapy plus levocarnitine treatment. The cardiac toxicity oc-curred after 4 cycles of epirubicin chemotherapy and the peripheral nerve toxicity occurred after 4 cycles of paclitaxel chemotherapy were observed. Results There was significant difference ( P <0. 05 ) between control group and treat-ment group in the incidences of abnormal ECG (70% vs.25%),the cTnI values[(0. 20±0. 12)μg/L vs.(0. 12±0. 08) μg/L],the CK-MB values [(25. 15±7. 80)U/L vs.(20. 05±5. 17)U/L],and the incidences of the peripher-al nerve toxicity(75% vs.35%). Conclusion Levocarnitine combined with chemotherapy can reduce myocardial cell injury induced by epirubicin and peripheral nerve toxicity caused by paclitaxel.